Security
ANEB · Anebulo Pharmaceuticals, Inc.
ANEBOTCCommon stockCurrentCIK 1815974Updated Sep 25, 2026
ANEB price & chart
Loading TradingView…
OTC:ANEB on TradingView ↗About the company
Anebulo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing novel solutions for people suffering from cannabis-induced toxicity. Its lead product candidate, selonabant, has completed a Phase 2 clinical trial evaluating its utility in blocking and reversing the negative effects of acute cannabinoid intoxication in healthy adults challenged with oral THC. Rather than proceeding directly with Phase 3 studies of oral selonabant in adults with ACI, the Company is prioritizing the advancement of a selonabant IV formulation as a potential treatment for pediatric patients with acute cannabis-induced toxicity, which it believes offers the potential for a faster timeline to approval relative to the adult oral product. Anebulo has scaled up the intravenous formulation for initial clinical safety studies, and initiated a Phase 1 SAD study of IV selonabant in September 2025. Selonabant is a competitive antagonist at the human CB1 receptor. For further information about Anebulo, please visit www.anebulo.com.
In the news
No coverage from other publishers is available.
Recent filings
15-12G filing
25 filing
SCHEDULE 13G/A - filed by Nantahala Capital Management, LLC regarding Anebulo Pharmaceuticals, Inc.
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · Other Events
Items 3.01, 8.01, 9.01
SC 13E3/A filing
Other Events
Items 8.01, 9.01
SC 13E3/A filing
Other Events
Items 8.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 12,145,616Source | 4,073,114Source | 11,670,151Source | 15,579,431Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 11,627,849Source | 3,094,200Source | — | — |
| Assets, CurrentUSD | 11,962,506Source | 3,507,990Source | — | — |
| Other Assets, NoncurrentUSD | 183,110Source | 565,124Source | — | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 487,688Source | 260,583Source | 1,068,801Source | 512,531Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 41,086Source | 25,934Source | 25,634Source | 23,345Source |
| Additional Paid in CapitalUSD | 85,505,349Source | 69,190,341Source | 67,777,757Source | 60,513,258Source |
| Retained Earnings (Accumulated Deficit)USD | -73,888,507Source | -65,403,744Source | -57,202,041Source | -45,469,703Source |
| Stockholders' Equity Attributable to ParentUSD | 11,657,928Source | 3,812,531Source | 10,601,350Source | 15,066,900Source |
| Liabilities and EquityUSD | 12,145,616Source | 4,073,114Source | 11,670,151Source | 15,579,431Source |
| Current liabilities: | ||||
| Accounts Payable, CurrentUSD | 224,175Source | 156,426Source | 534,545Source | 380,828Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 263,513Source | 104,157Source | 534,256Source | 131,703Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 1,446,824Source | 758,884Source | 884,723Source | 480,661Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 67,749Source | -378,119Source | 153,717Source | 270,780Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -6,349,687Source | -8,090,849Source | -9,683,133Source | -5,437,174Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 14,883,336Source | -62,354Source | 6,382,065Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 8,533,649Source | -8,153,203Source | -3,301,068Source | -5,437,174Source |
| Additional Financial Items | ||||
| Amortization of Debt Issuance CostsUSD | 382,014Source | 151,230Source | — | — |
| General and Administrative ExpenseUSD | 4,923,540Source | 4,759,818Source | 6,183,402Source | 3,869,636Source |
| InterestExpenseNonoperatingUSD | 382,014Source | 151,230Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -8,484,763Source | -8,201,703Source | -11,732,338Source | -6,825,619Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -6,825,619Source |
| Nonoperating Income (Expense)USD | 738,718Source | 107,052Source | 51,261Source | 5,555Source |
| Operating ExpensesUSD | 9,223,481Source | 8,308,755Source | 11,783,599Source | 6,831,174Source |
| Other Nonoperating Income (Expense)USD | -1,195Source | 9,260Source | -41,146Source | -1,777Source |
| Payments of Financing CostsUSD | 116,664Source | — | — | — |
| Proceeds from Issuance of Common StockUSD | 15,000,000Source | — | 6,646,748Source | — |
| Proceeds from Stock Options ExercisedUSD | — | — | 52,400Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -9,223,481Source | -8,308,755Source | -11,783,599Source | -6,831,174Source |
| Other Nonoperating Income (Expense)USD | -1,195Source | 9,260Source | -41,146Source | -1,777Source |
| Net Income (Loss) Attributable to ParentUSD | -8,484,763Source | -8,201,703Source | -11,732,338Source | -6,825,619Source |
| Earnings Per Share, BasicUSD per share | -0.25Source | -0.32Source | 0.47Source | -0.29Source |
| Earnings Per Share, DilutedUSD per share | -0.25Source | -0.32Source | 0.47Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 33,820,306Source | 25,822,258Source | 25,074,481Source | 23,344,567Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 33,820,306Source | 25,822,258Source | 25,074,481Source | — |
| Interest Expense (non-operating)USD | 382,014Source | 151,230Source | — | — |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 4,923,540Source | 4,759,818Source | 6,183,402Source | 3,869,636Source |
| Interest ExpenseUSD | 400,000Source | — | — | — |
| Interest Income, OtherUSD | 257,913Source | 249,022Source | 92,407Source | 7,332Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -6,825,619Source |
| Nonoperating Income (Expense)USD | 738,718Source | 107,052Source | 51,261Source | 5,555Source |
| Operating ExpensesUSD | 9,223,481Source | 8,308,755Source | 11,783,599Source | 6,831,174Source |
| Research and Development ExpenseUSD | 4,299,941Source | 3,548,937Source | 5,600,197Source | 2,961,538Source |
Filing attachments
ex99-1.htm · 8-K · 2026-02-12
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Updates AUSTIN, Texas (February 12, 2026) - Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced financial results for the three months ended December 31, 2025, and recent updates. Second …
Read attachment ↗ex99-1.htm · 8-K · 2026-02-06
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Anebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SEC AUSTIN, Texas (February 6, 2026) - Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced that the Company’s board of directors (the “Board”) has approved the voluntary delisting of t…
Read attachment ↗ex99-1.htm · 8-K · 2026-01-29
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Anebulo Pharmaceuticals Announces Final Results of Tender Offer AUSTIN, Texas (January 29, 2026) - Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced the final results of its voluntary self-tender offer to purchase 300,000 shares of its common stock, par value $0.001 per share (“C…
Read attachment ↗ex99-1.htm · 8-K · 2026-01-27
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Anebulo Pharmaceuticals Announces Preliminary Results of Tender Offer AUSTIN, Texas (January 27, 2026) - Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced the preliminary results of its voluntary self-tender offer to purchase 300,000 shares of its common stock, par value $0.001 p…
Read attachment ↗ex99-1.htm · 8-K · 2025-12-22
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Anebulo Pharmaceuticals Announces Its Intent to Commence a Self Tender Offer AUSTIN, Texas (December 22, 2025) - Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced that the Board of Directors has decided to commence a cash tender offer as part of its plan to “go private” in lieu o…
Read attachment ↗ex99-1.htm · 8-K · 2025-11-13
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2026 Financial Results and Recent Updates AUSTIN, Texas (November 13, 2025) - Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced financial results for the three months ended September 30, 2025, and recent updates. First Q…
Read attachment ↗